alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 49.4261-7 Examples of payments subject to tax. The following are examples of payments for transportation which, unless otherwise exempt under section 4261, 4281, 4282, or 4293 of the Internal Revenue Code are subject to tax: ( a ) *Cash fares.* The tax applies to payments of so-called “cash fares” where no ticket or other evidence of the right to transportation is issued to the passenger.
( b ) [Reserved]
( c ) *Additional charges.* Amounts paid as additional charges for changing the class of accommodations, changing the destination or route, extending the time limit of a ticket, as “extra fare”, or for exclusive occupancy of a section, etc., are subject to the tax.
( d ) - ( e ) [Reserved]
( f ) *Prepaid orders, exchange orders, or similar orders.* The tax applies to the amounts paid for prepaid orders, exchange orders, or similar orders for transportation. Additional amounts paid in procuring transportation in connection with the use of prepaid orders, exchange orders, or similar orders, are likewise subject to tax.
( g ) [Reserved]
( h ) *Aircraft charters.* ( 1 ) When no charge is made by the charterer of an aircraft to the persons transported, the amount paid by the charterer for the charter of the aircraft is subject to tax.
( 2 ) The charterer of an aircraft who sells transportation to other persons must collect and account for the tax with respect to all amounts paid to the charterer by such other persons. In such case, no tax will be due on the amount paid by the charterer for the charter of the aircraft but it shall be the duty of the owner of the aircraft to advise the charterer of the charterer's obligation for collecting, accounting for, and paying over the tax to the Internal Revenue Service.
( i ) *All-expense tours.* Amounts paid for all-expense tours are subject to tax with respect to that portion representing transportation which is subject to tax. See §§ 49.4261-2(c) and 49.4261-8(f)(4).
( j ) *Payments remitted to foreign countries by persons in the United States.* Payments for transportation tickets, prepaid orders, exchange orders, or similar orders are subject to the tax where the payment for such tickets or orders is accomplished by the purchaser either ( 1 ) by transmission from within the United States via telegraph or mail of cash, checks, postal or telegraphic money orders, and similar drafts to ticket offices or travel agencies, etc., located in any place without the United States, or
( 2 ) by the delivery of the funds to an agency located in the United States for transmission to ticket offices, or travel agencies, etc., without the United States. Such payments are considered to be payments made within the United States.
( k ) *Applicability date.* Paragraph (h) of this section applies to amounts paid on and after January 19, 2021. For rules that apply before that date, *see* 26 CFR part 49, revised as of April 1, 2020.
[T.D. 6430, 24 FR 9665, Dec. 3, 1959, as amended by T.D. 6618, 27 FR 11223, Nov. 14, 1962; T.D. 9948, 86 FR 5003, Jan. 19, 2021]
§ 48.4052-1 Heavy trucks and trailers; certification requirement. ( a ) *In general.* Tax is not imposed by section 4051 on the sale of an article for resale or leasing in a long-term lease if, by the time of sale, the seller has in good faith accepted from the buyer a statement that the buyer executed in good faith and that is in substantially the same form, and subject to the same conditions, as the certificate described in § 145.4052-1(a)(6) of this chapter, except that the certificate must be signed under penalties of perjury and need not refer to Form 637 or include a registration number.
( b ) *References to § 145.4052-1(a)(2) of this chapter .* References to § 145.4052-1(a)(2) of this chapter appearing in § 145.4052-1 of this chapter apply also to paragraph (a) of this section.
( c ) *Effective date.* This section is applicable after June 30, 1998. In addition, tax is not imposed on a sale occurring after December 31, 1997, and before July 1, 1998, if the conditions of paragraph (a) of this section are satisfied.
[T.D. 8879, 65 FR 17155, Mar. 31, 2000]
First Amendment to Commercial Paper Dealer Agreement



 Exhibit 10.03 
 FIRST AMENDMENT TO COMMERCIAL PAPER DEALER AGREEMENT 
 THIS FIRST AMENDMENT TO COMMERCIAL PAPER DEALER AGREEMENT (the “First Amendment”) is entered into on this 28th day of February, 2007 by and between Cardinal Health, Inc. (“Issuer”) and Banc of America Securities LLC (“Dealer”). 
 Background Information 
 A. Issuer and Dealer are parties to that certain
Commercial Paper Dealer Agreement dated August 9, 2006 (the “Agreement”) concerning notes issued pursuant to that certain Issuing and Paying Agency Agreement also dated August 9, 2006 by and between Issuer and The Bank of New
York (the “Issuing and Paying Agency Agreement”). 
 B. The Issuer desires to increase to $1,500,000,000 the limit as to the
aggregate principal amount of commercial paper notes which may be outstanding at any given time under the 4(2) Commercial Paper Program established by the Issuing and Paying Agency Agreement, the Agreement, and other related agreements. 

Agreement 
 The parties
hereby acknowledge the accuracy of the foregoing Background Information and agree as follows: 
 1. Defined Terms. Unless the
context as used herein requires otherwise, capitalized terms used but not defined in this First Amendment shall have the meaning given to them in the Agreement. 
 2. Amendment. The centered paragraph underneath the line on page one (the cover page) of the Agreement is hereby deleted in its entirety and restated as follows: 
 Between: Cardinal Health, Inc., as Issuer and Banc of America Securities LLC, as Dealer Concerning Notes to be issued pursuant to an Issuing and Paying
Agency Agreement dated as of August 9, 2006, as amended February 28, 2007, between the Issuer and the Bank of New York, as Issuing and Paying Agent, Dated as of August 9, 2006, as amended February 28, 2007. 
 3. No Other Modifications. Except as expressly provided in this First Amendment, all of the terms and conditions of the Agreement shall
remain unchanged and in full force and effect. 
 4. Binding Effect. This First Amendment shall be binding upon and inure to
the benefit of the parties hereto and their respective successors and assigns. 







 5. Governing Law. This First Amendment shall be governed by and construed in accordance
with the laws of the State of New York. 
 6. Conflict. In the event of any inconsistency or conflict between this First
Amendment and the Agreement, the terms, provisions and conditions of this First Amendment shall govern and control. 
 7.
Counterparts. This First Amendment may be executed in separate counterparts, each of which shall be deemed to be an original but all of which shall constitute one and the same instrument. 
 (Signatures on following page.) 







 The parties hereto have executed this First Amendment as of the day and year first written above.

  

							
	CARDINAL HEALTH, INC.	 	BANC OF AMERICA SECURITIES LLC
				
	By:	 	 /s/ Linda S. Harty
	 	By:	 	 /s/ Robert Porter

	Name:	 	Linda S. Harty, as Executive	 	Name:	 	Robert Porter
		 	Vice President and Treasurer	 		 	
				
	Date:	 	2-28-2007	 	Date:	 	2/27/07
**EXHIBIT 32.1**

 

**Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted  Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

 

In connection with the Quarterly Report on Form 10-Q of Merit Medical Systems, Inc. (the”Company”) for the quarter ended March 31, 2011 (the “Report”), I, Fred P. Lampropoulos, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

 

(1)   The Report fully complies with the requirements of Section 13(a) or 15 (d) of the Securities Exchange Act of 1934; and

 

(2)   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 
| Date:   May 9, 2011 | /s/   Fred P. Lampropoulos              |
|--------------------------|-----------------------------------------|
|                     | Fred   P. Lampropoulos                  |
|                     | President   and Chief Executive Officer |
|                     | (principal   executive officer)         |

 

This certification accompanies the foregoing Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.  A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

1

----
```

[Congressional Bills 104th Congress]
[From the U.S. Government Publishing Office]
[H.J. Res. 88 Introduced in House (IH)]

104th CONGRESS
  1st Session
H. J. RES. 88

  Proposing an amendment to the Constitution of the United States to 
   provide that no person born in the United States will be a United 
States citizen on account of birth in the United States unless a parent 
          is a United States citizen at the time of the birth.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                              May 17, 1995

 Mr. Callahan (for himself, Mr. Stump, Mr. Everett, and Mr. Traficant) 
 introduced the following joint resolution; which was referred to the 
                       Committee on the Judiciary

_______________________________________________________________________

                            JOINT RESOLUTION

 
  Proposing an amendment to the Constitution of the United States to 
   provide that no person born in the United States will be a United 
States citizen on account of birth in the United States unless a parent 
          is a United States citizen at the time of the birth.
    Resolved by the Senate and House of Representatives of the United 
States of America in Congress assembled (two-thirds of each House 
concurring therein), That the following article is proposed as an 
amendment to the Constitution of the United States, which shall be 
valid to all intents and purposes as part of the Constitution when 
ratified by the legislatures of three-fourths of the several States 
within seven years after the date of its submission to the States for 
ratification:

                              ``Article --
    ``Section 1. No person born in the United States after the date of 
the ratification of this article shall be a citizen of the United 
States, or of any State, on account of birth in the United States 
unless the mother or father of the person is a citizen of the United 
States at the time of the birth.
    ``Sec. 2. The Congress shall have power to enforce this article by 
appropriate legislation.''.
                                 <all>
```
To: Docket Management Facility US Department ofTransportation 1200 NewJerseyAve. SE Washington, DC 20590 Subject: Request for Exemption Relative to Issuing Airworthiness 8130-3 Tags (Domestic and Export) per FAA Orders 8100.15 and 8130.21

Problem Statement Manyforeign and some domestic customers ofWencor, LLC, a world-wide distributorofaircraft parts, are demanding the issuance of8130-3Airworthiness Approval Tags forall standard parts. Typically, the FAA has authorized ODARs and ODAs to only apply the 8130-3tags to PMA articles produced by ourcompany. It has been incumbent upon Wencorto hire an independent DAR to perform this service. Wencor has both the FAA-approved Fabrication Inspection System (FIS) per 14 CFR Part 21, section 21.303(h) and a Total Aerospace Quality System, certified by a 3rd partyto ISO 9001 and AS 91008. We have an effective Supplier Quality system and maintain complete lot traceability to supplier certifications and test reports. Since we have ISOcertified inspection procedures and FAA-delegated inspectors on-staff performing airworthiness inspections ofour PMA parts, the additional activity ofperforming airworthiness inspections and certifying standard parts does not require additional capabilities. It would be much more cost effective and timelyfor us to use ourfull-time staff ratherthan to contract an outside DAR to perform this function. Exemption Requested Wencor is requesting that you allowfull-time in-house FAA-designated personnel to issue 8130- 3 airworthiness tags for all standard parts (as defined by FAA documentation such as 14 CFR 21.303(b)(4), AC 20-62 par. 4.b.(1) and AC 21-29, par. 3.b(8) & 3.1.) as long as the manufacturer is an approved supplierand full lot traceability has been maintained.

Solution: We request an FAA exemption to mitigate the serious cost and schedule impactto our business as a U.S. aircraft parts manufacturerand distributorselling to the global marketplace.

Please contact 

### K. DickVaughn, Wencor FAA Specialist (e-mail: dvaughn@wencor.com or phone number801-491-2515) for more details orquestions on this proposal. Sincerely,

Russ Adamson, President Wencor, LLC 1625 North 1100West Springville, UT84663
[if !vml]>[endif]>

[if !vml]>[endif]>

You have reached the FederalDepository Library Program Electronic Collection (FDLP/EC) Archive. Thisarchive assures ongoing access to publications in the FDLP/EC. Access topublications in the archive is available through GPO's suite of cataloging andlocator services, including the Catalog of U.S. Government Publications(CGP).  Archived copies of publications are retrieved in the event thatpublications are no longer available from the original publishing agency site. 
**Title:****Motor vehicle use map. AshleyNational Forest, Utah. Duchesne Ranger District, South Unit**
 
2013:Front | Back
2014:Front | Back
2016:Front | Back
 
SuDoc Number:A 13.28:AS 3/13/
Item Number:0080-G (online)
CGP systemNumber:000924141
 
January 11, 2018
§ 1023.630 Prohibition on correspondent accounts for foreign shell banks; records concerning owners of foreign banks and agents for service of legal process. ( a ) Refer to § 1010.630 of this chapter.
( b ) [Reserved]
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS NINE MONTH YEAR-TO-DATE SUMMARY FINANCIAL
INFORMATION EXTRACTED FROM AMERICAN BIOGENETIC SCIENCES INC. 1996
THIRD QUARTER FORM 10-Q SEPTEMBER 30,1996
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1995
<PERIOD-END>                               SEP-30-1996
<CASH>                                       7,187,000
<SECURITIES>                                 5,721,000
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                            15,908,000
<PP&E>                                       1,681,000
<DEPRECIATION>                               1,116,000
<TOTAL-ASSETS>                              18,085,000
<CURRENT-LIABILITIES>                          622,000
<BONDS>                                     10,900,000
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        17,000
<OTHER-SE>                                   6,534,000
<TOTAL-LIABILITY-AND-EQUITY>                18,085,000
<SALES>                                              0
<TOTAL-REVENUES>                                34,000
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                             1,952,000
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             318,000
<INCOME-PRETAX>                            (4,574,000)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (4,574,000)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (4,574,000)
<EPS-PRIMARY>                                    (.29)
<EPS-DILUTED>                                    (.29)
        

</TABLE>
T hi s di s pos i t i on i s notappr opr i a t e f orpubl i c a t i on and i s notpr e c e de nt * e xc e pta s pr ovi de d by9th C i r . R . 36- 3.

T he pane l una ni m ous l yc onc l ude s thi s c a s e i s s ui t abl e f orde c i s i on ** w ith o u t o r a l ar g u m e n t. See F ed. R . A pp . P . 34 (a )( 2). NOT F OR P UB L I CAT I ON UN I TE D STATE S C OU RT OF APPE ALS FOR T HE NI NTH CI RC UI T
J. JE S U S L O P E Z -C E R V A N T E S , a. k. a. J e s us L ope z C e rvant e s , a . k. aJ e s us C ervant es -L op ez , P et i t i on er , v. E R I C H . H O L D E R , J r ., A tto rn e yG e n e r a l, R e s p o n d e n t. N o. 12- 71167 A ge nc yN o. A 075- 128- 451 ME MOR AN DU M *

O n P e t i t i on f

orR e vi e w of

a n O r de rof

the B o ar do f I m m ig r a tio n A p p e a ls S ubm i tt e d A ugus t14, 2013 ** B efo re: S C H R O E D E R , G R A B E R , an dP A E Z , C i rcu i tJu d g es. J . J e s us L ope z - C e rvant e s , ana t i ve a nd c i t i z e n of M e xi c o, pe t i t i ons f

or r e vi e w of

the B oar d of

I m m i gr a t i on A ppe a l s ’ or de rs um m ar i l ya f f i rm i ng ade c i s i on of an i m m i grat i on j ud ge (“ IJ ”) denyi ng hi s app l i cat i on for c ance l l at i on of re m ov al 

# FI LED AU G 16 2013 M OLLY C. DW Y ER, CLERK U
. S. C O U R T OF APPE ALS12- 71167 2 in th e e x e r c is e o f

d is c r e tio n . O u rju r is d ic tio n is g o v e rn e db y8 U .S .C . § 1 2 5 2 . W e d i s m i s s th e p e t i t i o n f

o rr e v i e w. W e la c kju r is d ic tio n to r e v ie w th e I J ’s d e n ia l o f c an c e lla tio n o f

r e m o v a l in th e e x e r c is e o f

d is c r e tio n . See B erm udezv. H older , 58 6 F . 3d 11 67 , 11 69 (9th C i r. 20 09 ) ( per c uri am ). M oreover, L op ez -C ervant es ’ s c on t ent i on thatthe agency f a i l e d t o c ons i de rhi s e vi de nc e i s notas uf f i c i e nt l yc ol or abl e c ons t i tut i ona l c l a i m or q u e s tio n o f

law to tr ig g e ro u rju r is d ic tio n . See Mendez- Castro v. Mukasey , 552 F . 3d 975, 978 ( 9th C i r . 2009) ( “ T o be c ol or abl e i n thi s c ont e xt , the vi ol a t i on ne e d notbe s ubs t ant i a l , butthe c l a i m m us tha ve s om e pos s i bl e va l i di ty . ” ( c i t a t i on and i nt ernal qu ot at i on m arks om i tt ed)) . P E T I T I ON F OR RE V I E W DI S MI S S E D.
Exhibit 10.18


AMENDMENT NO. 1 TO NOTE
PURCHASE AGREEMENT


January 4, 2007


John
A, Keller


Incyte
Corporation


Experimental
Station-E336/228


Route
141 & Henry Clay Road


Wilmington, DE 
19880


Re:         Amendment
No. 1 to Note Purchase Agreement


Dear Mr. Keller,


This letter makes reference to the Note Purchase
Agreement (the “Note Purchase Agreement”), dated as of November 18, 2005,
between Incyte Corporation (“Incyte”) and Pfizer Overseas Pharmaceuticals. (“Pfizer”).
Capitalized terms used herein and not otherwise defined shall have the meanings
assigned to them in the Note Purchase Agreement.


Incyte and Pfizer hereby agree that the last sentence
of Section 2.1(b) of the Note Purchase Agreement shall be amended and
restated as set forth below:


“The Company shall have the right to exercise its
option pursuant to this Section 2.1(b) at any time (x) after the
first date on which the Company can lawfully test a given indication in humans
pursuant to the filing of the first IND for an Incyte Compound under the
License Agreement and prior to September 28, 2007 and (y) the
delivery by the Company to the Investor of written confirmation that the
Company will use commercially reasonable efforts to continue clinical
development of the Incyte Compound referred to in clause (x) (the
satisfaction of the matters specified in clauses (x) and (y), the “Second
Tranche Trigger Date”) by delivering to the Investor written notice of its
election to issue the Additional Note.”


Except as otherwise specifically stated herein, all
other terms of the Note Purchase Agreement remain in full force and effect.


This letter amendment shall be governed by and
construed under the laws of the State of New York (irrespective of its choice
of law principles).


This letter amendment may be signed in one or more
counterparts, each of which, when executed, shall be deemed to be an original
and all of which together shall constitute one and the same document.


Please
sign below to confirm your agreement with the foregoing.




	
   

  	
   

  	
  Sincerely,

  
	
   

  	
   

  	
  Pfizer Overseas
  Pharmaceuticals

  
	
   

  	
   

  	
  /s/ PETER DUFFY

  	
   

  
	
   

  	
   

  	
  Name:

  	
  PETER DUFFY

  
	
   

  	
   

  	
  Title:

  	
  DIRECTOR

  
	
   

  	
   

  	
  /s/ PAUL DUFFY

  	
   

  
	
   

  	
   

  	
  Name:

  	
  PAUL DUFFY

  
	
   

  	
   

  	
  Title:

  	
  DIRECTOR

  
	
  Accepted and
  agreed on behalf of

  	
   

  	
   

  
	
  Incyte
  Corporation:

  	
   

  	
   

  
	
  /s/ PATRICIA A. SCHRECK

  	
   

  	
   

  	
   

  
	
  Name:

  	
  PATRICIA A.
  SCHRECK

  	
   

  	
   

  
	
  Title:

  	
  GENERAL
  COUNSEL
(logo) pwc

 

 

**Report of IndependentRegistered Public Accounting Firm**

 

 

To the Board of Directors andshareholders of CoreLogic, Inc.:

 

We have examined management’s assertion,included in the accompanying Report on Assessment of Compliance, that CoreLogicCommercial Real Estate Services, Inc. (the "Company"), a subsidiaryof CoreLogic, Inc. complied with the servicing criteria set forth in Item1122(d) of the Securities and Exchange Commission's Regulation AB for all loansfor commercial mortgage loan outsourcing customers for which the Company servedas the commercial tax service provider (the "Platform"), as ofDecember 31, 2016 and for the year then ended, only including 1122(d)(1)(iv),1122(d)(2)(ii), 1122(d)(2)(v), 1122(d)(2)(vi), 1122(d)(2)(vii), 1122(d)(4)(xi),1122(d)(4)(xii) and 1122(d)(4)(xiii), which the Company has determined areapplicable to the servicing activities performed by it with respect to the Platform.Management is responsible for the Company's compliance with the servicingcriteria. Our responsibility is to express an opinion on management's assertionbased on our examination.

 

Our examination was conductedin accordance with attestation standards of the Public Company AccountingOversight Board (United States) and, accordingly, included examining, on a testbasis, evidence about the Company’s compliance with the applicable servicingcriteria and performing such other procedures as we considered necessary in thecircumstances. Our examination included testing of selected servicingactivities related to the Platform, and determining whether the Companyperformed those selected activities in compliance with the applicable servicingcriteria. Our procedures were limited to the selected servicing activitiesperformed by the Company during the period covered by this report. Ourprocedures were not designed to detect noncompliance arising from errors thatmay have occurred prior to or subsequent to our tests that may have affectedthe balances or amounts calculated or reported by the Company during the periodcovered by this report. We believe that our examination provides a reasonablebasis for our opinion. Our examination does not provide a legal determinationon the Company’s compliance with the servicing criteria.

 

In our opinion, management’sassertion that the Company complied with the aforementioned applicableservicing criteria as of and for the year ended December 31, 2016 for all loansfor commercial mortgage loan outsourcing customers for which the Company servedas the commercial tax service provider is fairly stated, in all materialrespects.

 

/s/ PricewaterhouseCoopers

 

February 6, 2017

 

 

*PricewaterhouseCoopers LLP,2001 Ross Avenue, Suite 1800, Dallas TX 75201-2997*

*T: 214-746-6500, F:214-712-6660,*www.pwc.com